Pregnancy vaccine shields infants from RSV — real-world study launched
NCT ID NCT06647654
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 26 times
Summary
This study looks at how effective the ABRYSVO® vaccine is when given to pregnant women to protect their babies from RSV, a serious respiratory virus. Researchers will review medical records of infants up to 9 months old who were hospitalized with breathing problems. The goal is to see if the vaccine reduces hospitalizations and severe illness in real-world conditions across Argentina and Uruguay.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Buenos Aires, Argentina
Conditions
Explore the condition pages connected to this study.